Biomarin Pharmaceutical Inc (BMRN) – aksjekurser og nyheter

Symboler Symboler	Pris	Endring	Endring (%)	Trend	Forrige pris ved stengetid	Åpne	Høy	Lav	Volum	Markedsverdi
SIXB Materials SIXB Materials	SIXB −1,41%	1 076,13	−15,38	−1,41%	—	1 091,51	1 090,40	1 090,40	1 073,69	—	—
SIXC Communications SIXC Communications	SIXC −0,55%	606,74	−3,37	−0,55%	—	610,11	610,11	610,29	606,17	—	—
SIXE Energy SIXE Energy	SIXE +0,88%	1 248,82	+10,84	+0,88%	—	1 237,98	1 237,83	1 252,41	1 225,03	—	—
SIXI Industrials SIXI Industrials	SIXI −1,17%	1 724,36	−20,35	−1,17%	—	1 744,71	1 740,95	1 747,29	1 721,57	—	—
SIXM Financials SIXM Financials	SIXM −0,72%	635,59	−4,59	−0,72%	—	640,18	639,92	643,19	634,73	—	—
SIXR Staples SIXR Staples	SIXR −0,76%	843,15	−6,43	−0,76%	—	849,58	845,27	851,68	839,47	—	—
SIXRE Real estate SIXRE Real estate	SIXRE −0,55%	216,29	−1,19	−0,55%	—	217,48	217,48	218,16	215,51	—	—
SIXT Technology SIXT Technology	SIXT +0,08%	3 263,41	+2,72	+0,08%	—	3 260,69	3 273,36	3 287,81	3 240,78	—	—
SIXU Utilities SIXU Utilities	SIXU −0,34%	939,24	−3,21	−0,34%	—	942,45	939,39	948,80	933,98	—	—
SIXV Health care SIXV Health care	SIXV −0,29%	1 462,56	−4,24	−0,29%	—	1 466,80	1 464,70	1 467,19	1 458,36	—	—
SIXY Discretionary SIXY Discretionary	SIXY −0,71%	2 380,40	−17,10	−0,71%	—	2 397,50	2 395,03	2 412,01	2 370,64	—	—

Inntekt Q1 2026 • utgitt • EPS sto ikke til forventningene −16,86% • Inntektene overgikk forventningene +1,93%

Se resultatene

BMRN:NASDAQ

Biomarin Pharmaceutical Inc

55,46 USD

+2,59%

(+1,40) 1 D

54,87 USD

−1,06% (−0,59)

Etter stengetid

Stengt: 4. mai, 16:00:01 GMT-4 · USD

Alle symboler

1 D

5 D

1 M

6 M

I år

1 Å

5 Å

MAKS

	Symbol	Pris	Endring	Endring (%)

Genererer viktig statistikk for BMRN …

Åpne

53,66 USD

Høy

55,53 USD

Lav

53,45 USD

Markedsverdi

10,72 mrd.

Snittvolum

1,65 mill.

Volum

2,83 mill.

P/E-forhold

30,73

52 u høy

66,28 USD

52 u lav

50,76 USD

EPS

1,80 USD

Beta

0,23

Utestående aksjer

192,32 mill.

Antall ansatte

Relaterte aksjer

RVMD

Revolution Medicines Inc

Sarepta Therapeutics Inc

22,04 USD

+2,56%

Nyhetssaker

Fra kilder på nettet

IndexBox

for 3 timer siden

BioMarin Q1 2026 Earnings Preview: Revenue Growth Expected to Slow - News and Statistics

Yahoo Finance

for 4 timer siden

Compared to Estimates, BioMarin (BMRN) Q1 Earnings: A Look at Key Metrics

AOL.com

for 5 timer siden

BioMarin (BMRN) Q1 2026 Earnings Transcript

TradingView

for 5 timer siden

BMRN: Amicus acquisition drives 20% 2026 revenue growth outlook and portfolio expansion

Profil

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria. Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia

Om Biomarin Pharmaceutical Inc

Administrerende direktørAlexander Hardy

Ansatte3,22k

Grunnlagtmars 1997

HovedkontorSan Rafael, California, USA

Sektor-

Nettstedbiomarin.com

Alle verdier i USD	mars 2025	juni 2025	sep. 2025	des. 2025
Inntekt	745,14 mill.	825,41 mill.	776,13 mill.	874,56 mill.
Varekostnad	310,29 mill.	311,40 mill.	549,56 mill.	348,91 mill.
Direkte driftskostnader	310,29 mill.	311,40 mill.	549,56 mill.	348,91 mill.
Utgifter til forskning og utvikling	-	-	-	-
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	206,12 mill.	232,28 mill.	268,42 mill.	324,16 mill.
Driftskostnader	210,96 mill.	237,12 mill.	273,26 mill.	329,01 mill.
Totale driftskostnader	521,25 mill.	548,52 mill.	822,82 mill.	677,92 mill.
Driftsinntekter	223,89 mill.	276,89 mill.	−46,69 mill.	196,64 mill.
Andre ikke-operasjonelle inntekter	−1,95 mill.	4,83 mill.	5,09 mill.	1,02 mill.
EBT inkludert uvanlige elementer	238,09 mill.	297,87 mill.	−26,32 mill.	−27,15 mill.
EBT uten uvanlige elementer	238,09 mill.	297,87 mill.	−26,32 mill.	214,10 mill.
Kostnad for inntektsskatt	52,40 mill.	57,34 mill.	4,42 mill.	19,42 mill.
Faktisk avgiftssats	22,01 %	19,25 %	−16,79 %	−71,52 %
Andre driftskostnader	-	-	-	-
Nettoinntekt	185,69 mill.	240,53 mill.	−30,74 mill.	−46,57 mill.
Netto fortjenestemargin	24,92 %	29,14 %	−3,96 %	−5,33 %
Resultat per aksje	1,13	1,44	0,12	0,46
Rente- og investeringsinntekter	19,01 mill.	18,83 mill.	17,85 mill.	19,21 mill.
Rentekostnader	−2,86 mill.	−2,68 mill.	−2,58 mill.	−2,78 mill.
Netto rentekostnader	16,15 mill.	16,15 mill.	15,28 mill.	16,43 mill.
Avskrivnings- og amortiseringskostnader	-	-	-	-
EBITDA	245,96 mill.	295,45 mill.	−28,20 mill.	209,68 mill.
Gevinst eller tap ved salg av eiendeler	-	-	-	-

AI-innhold kan inneholde feil. Finn ut mer

HjelpSend tilbakemeldingPersonvern Vilkår Ansvarsfraskrivelse

Finance

Utforskning